GLOBAL PERSPECTIVES ON ADR MONITORING: A COMPARATIVE REVIEW OF PHARMACOVIGILANCE SYSTEM

Payal Bansode*, Yogeshwari Jadhav*, Manasi Autade, Shivani Chinchkar, Smt. Ankita Kore

Pharmacovigilance (PV) is necessary to implement drug safety measures and reduce adverse drug reactions all over the world. This review compares pharmacovigilance practices in various countries, including India, the United States, Malaysia, Singapore, Thailand, China, Nepal, Australia and European countries, highlighting the global nature of ADR surveillance systems. This study highlights the development of PV systems, their current status and the challenges they face, such as low reporting, lack of national recognition, varying regulatory frameworks and regulatory shortcomings. While developed countries generally have more mature systems, many developing countries are still building capacity. The part of the World Health Organization (WHO) in social development safety efforts is highlighted. A comparative analysis effectively reveals common barriers to ADR, including a lack of proper training, public reporting processes and low participation. Future directions Take advantage of emerging technologies such as AI, increase global assistance rates and reporting, and suggest disease-focused approaches to improve data quality. Improving drug safety surveillance systems is crucial to ensuring the safety of safe forms and enhancing clinical outcomes globally.